Molecular Pathways Molecular Pathways : Fibroblast Growth Factor Signaling : A New Therapeutic Opportunity in Cancer
暂无分享,去创建一个
[1] W. Sellers,et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF‐23 signaling and regulating FGF‐23 expression in bone , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] Pascal Furet,et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. , 2011, Journal of medicinal chemistry.
[3] Daohong Chen,et al. A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models , 2011, Molecular Cancer Therapeutics.
[4] M. Mohammadi,et al. Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. , 2011, American journal of physiology. Renal physiology.
[5] J. Wesche,et al. Fibroblast growth factors and their receptors in cancer. , 2011, The Biochemical journal.
[6] M. Dennis,et al. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4 , 2011, mAbs.
[7] J. Baselga,et al. A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Lincoln D. Stein,et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. , 2011, Cancer cell.
[9] L. Quarles,et al. Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. , 2011, American journal of physiology. Endocrinology and metabolism.
[10] T. Mohr,et al. Up‐regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis , 2011, Hepatology.
[11] I. Petersen,et al. Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.
[12] Nhi N. Y. Vo,et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. , 2010, Cancer research.
[13] Lihong V Wang,et al. Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts , 2010, Clinical Cancer Research.
[14] L. Medeiros,et al. 8p11 myeloproliferative syndrome: a review. , 2010, Human pathology.
[15] N. Turner,et al. Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.
[16] L. Staudt,et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. , 2009, The Journal of clinical investigation.
[17] M. Mohammadi,et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. , 2009, American journal of physiology. Renal physiology.
[18] D. Dornan,et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. , 2009, The Journal of clinical investigation.
[19] C. Der,et al. Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 Isoform* , 2009, Journal of Biological Chemistry.
[20] M. Mohammadi,et al. The FGF family: biology, pathophysiology and therapy , 2009, Nature Reviews Drug Discovery.
[21] P. Bunn,et al. Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells , 2009, Molecular Pharmacology.
[22] L. Quarles,et al. FGFR3 and FGFR4 do not mediate renal effects of FGF23. , 2008, Journal of the American Society of Nephrology : JASN.
[23] Gordon B. Mills,et al. Derailed endocytosis: an emerging feature of cancer , 2008, Nature Reviews Cancer.
[24] Kristian Cibulskis,et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma , 2008, Proceedings of the National Academy of Sciences.
[25] Cem Elbi,et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. , 2008, Cancer research.
[26] R. Carano,et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models , 2008, Oncogene.
[27] Ross S Berkowitz,et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Peter Bohlen,et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. , 2007, American journal of physiology. Endocrinology and metabolism.
[29] K. Okawa,et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.
[30] A. Joe,et al. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.
[31] N. Sebire,et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. , 2006, The EMBO journal.
[32] K. Rosenblatt,et al. Regulation of Fibroblast Growth Factor-23 Signaling by Klotho* , 2006, Journal of Biological Chemistry.
[33] B. Thisse,et al. Functions and regulations of fibroblast growth factor signaling during embryonic development. , 2005, Developmental biology.
[34] T. Dragani,et al. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. , 2005, Oncology reports.
[35] Alan P. Brown,et al. Cartilage Dysplasia and Tissue Mineralization in the Rat Following Administration of a FGF Receptor Tyrosine Kinase Inhibitor , 2005, Toxicologic pathology.
[36] V. P. Eswarakumar,et al. Cellular signaling by fibroblast growth factor receptors. , 2005, Cytokine & growth factor reviews.
[37] Shaun K Olsen,et al. Structural basis for fibroblast growth factor receptor activation. , 2005, Cytokine & growth factor reviews.
[38] P. Dell’Era,et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.
[39] Y. Shiratori,et al. Altered expression of vascular endothelial growth factor, fibroblast growth factor‐2 and endostatin in patients with hepatocellular carcinoma , 2005, Journal of gastroenterology and hepatology.
[40] Tomoko Iwata,et al. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[41] H. Joensuu,et al. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[42] G. Frantz,et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. , 2002, The American journal of pathology.
[43] J. Yang,et al. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. , 2001, Cancer research.
[44] M. Makuuchi,et al. Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. , 1999, Cancer research.
[45] D. Chopin,et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.
[46] M. C. Hu,et al. FGF-18, a Novel Member of the Fibroblast Growth Factor Family, Stimulates Hepatic and Intestinal Proliferation , 1998, Molecular and Cellular Biology.
[47] R. Zeillinger,et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. , 1997, Cancer research.
[48] T. Ueno,et al. Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. , 1997, Journal of hepatology.
[49] D. Becker,et al. Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth , 1997, Nature Medicine.
[50] E. Schröck,et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.
[51] C. MacArthur,et al. Receptor Specificity of the Fibroblast Growth Factor Family* , 1996, The Journal of Biological Chemistry.
[52] L. Shulman,et al. Genome-wide association study identifies novel breast cancer susceptibility loci , 2008 .
[53] D. Scheinberg,et al. Monoclonal antibody therapy of cancer. , 1990, Cancer chemotherapy and biological response modifiers.